A Phase 2b Open-Label Rollover Study For Subjects Discontinuing From UK-453,061 Studies For Treatment Of HIV-1 Infected Subjects.

Trial Profile

A Phase 2b Open-Label Rollover Study For Subjects Discontinuing From UK-453,061 Studies For Treatment Of HIV-1 Infected Subjects.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs Lersivirine (Primary) ; Darunavir; Efavirenz; Emtricitabine/tenofovir disoproxil fumarate; Etravirine; Nucleoside reverse transcriptase inhibitors; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 31 Jul 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 04 Apr 2011 Planned End Date changed from 1 Dec 2016 to 1 Aug 2017, as reported by ClinicalTrials.gov.
    • 01 Feb 2011 Additional location (Portugal) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top